AMENDMENTS TO THE CLAIMS

The following listing of claims replaces all prior listings of claims presented in the application.

1. (Currently amended) A compound of the ~~general~~ formula I



wherein

X is O, S or $CR^{11}R^{12}$, wherein R^{11} and R^{12} <u>are each</u> independently ~~are selected from~~ H or C_{1-6} alkyl;

Y is O or S;

R^1, R^2, R^3 and R^4 are <u>each</u> independently ~~selected from~~ hydrogen; halogen; cyano; nitro; C_{1-6}-alk(en/yn)yl; C_{1-6}-alk(en/yn)yloxy; C_{1-6}-alk(en/yn)ylsulfanyl; hydroxy; hydroxy-C_{1-6}-alk(en/yn)yl; halo-C_{1-6}-alk(en/yn)yl; halo-C_{1-6}-alk(en/yn)yloxy; C_{3-8}-cycloalk(en)yl; C_{3-8}-cycloalk(en)yl-C_{1-6}-alk(en/yn)yl; acyl; C_{1-6}-alk(en/yn)yloxycarbonyl; C_{1-6}-alk(en/yn)ylsulfonyl; aryl optionally substituted with a halogen, cyano, nitro, C_{1-6}-alk(en/yn)yl, C_{1-6}-alk(en/yn)yloxy, C_{1-6}-alk(en/yn)ylsulfanyl, hydroxy, hydroxy-C_{1-6}-alk(en/yn)yl, halo-C_{1-6}-alk(en/yn)yl, halo-C_{1-6}-alk(en/yn)yloxy, C_{3-8}-cycloalk(en)yl, C_{3-8}-cycloalk(en)yl-C_{1-6}-alk(en/yn)yl, acyl, C_{1-6}-alk(en/yn)yloxycarbonyl or C_{1-6}-alk(en/yn)ylsulfonyl; monocyclic heteroaryl optionally substituted with a halogen, cyano, nitro, C_{1-6}-alk(en/yn)yl, C_{1-6}-alk(en/yn)yloxy, C_{1-6}-alk(en/yn)ylsulfanyl,

hydroxy, hydroxy-C_{1-6}-alk(en/yn)yl, halo-C_{1-6}-alk(en/yn)yl, halo-C_{1-6}-alk(en/yn)yloxy, C_{3-8}-cycloalk(en)yl, C_{3-8}-cycloalk(en)yl-C_{1-6}-alk(en/yn)yl, acyl, C_{1-6}-alk(en/yn)yloxycarbonyl or C_{1-6}-alk(en/yn)ylsulfonyl; or $-NR^{13}R^{14}$ wherein R^{13} and R^{14} are each independently ~~are selected from~~ hydrogen, C_{1-6}-alk(en/yn)yl, C_{3-8}-cycloalk(en)yl, C_{3-8}-cycloalk(en)yl-C_{1-6} alk(en/yn)yl or aryl, or R^{13} and R^{14} together with the nitrogen atom to which they are attached form a 3-7-membered heterocyclic ring which optionally contains one further heteroatom selected from O, S and ~~or~~ N;

R^5 is aryl or monocyclic heteroaryl, optionally substituted with a halogen, cyano, nitro, C_{1-6}-alk(en/yn)yl, C_{1-6}-alk(en/yn)yloxy, C_{1-6}-alk(en/yn)ylsulfanyl, hydroxy, hydroxy-C_{1-6}-alk(en/yn)yl, halo-C_{1-6}-alk(en/yn)yl, halo-C_{1-6}-alk(en/yn)yloxy, C_{3-8}-cycloalk(en)yl, C_{3-8}-cycloalk(en)yl-C_{1-6}-alk(en/yn)yl, acyl, C_{1-6}-alk(en/yn)yloxycarbonyl, C_{1-6}-alk(en/yn)ylsulfonyl or $-NR^{15}R^{16}$ wherein R^{15} and R^{16} are each independently ~~are selected from~~ hydrogen, C_{1-6}-alk(en/yn)yl, C_{3-8}-cycloalk(en)yl, C_{3-8}-cycloalk(en)yl-C_{1-6} alk(en/yn)yl or aryl, or R^{15} and R^{16} together with the nitrogen atom to which they are attached form a 3-7-membered heterocyclic ring which optionally contains one further heteroatom selected from O, S and ~~or~~ N;

R^6 is ~~selected from~~ H, C_{1-6}-alk(en/yn)yl, C_{1-6}-alk(en/yn)yloxy, C_{1-6}-alk(en/yn)ylsulfanyl or C_{3-8}-cycloalk(en)yl, provided that when R^6 is ~~selected from~~ C_{1-6}-alk(en/yn)yloxy[[,]] or C_{1-6}-alk(en/yn)ylsulfanyl then X is $CR^{11}R^{12}$, wherein R^{11} and R^{12} are each independently ~~are selected from~~ H or C_{1-6} alkyl;

R^7 and R^8 are each independently ~~selected from~~ H, C_{1-6}-alk(en/yn)yl or C_{3-8}-cycloalk(en)yl;

R^9 and $R^{9'}$ are each independently ~~selected from~~ H, C_{1-6}-alk(en/yn)yl, hydroxy-C_{1-6}-alk(en/yn)yl, C_{1-6} alk(en/yn)ylsulfanyl-C_{1-6}-alk(en/yn)yl or C_{3-8}-cycloalk(en)yl; or

R^6 and R^8 together with the atoms to which they are attached and the intervening carbon atom ~~nitrogen~~ form a saturated 3-7 membered heterocyclic ring, and R^7 is ~~selected from~~ H, C_{1-6}-alk(en/yn)yl or C_{3-8}-cycloalk(en)yl, and R^9 and $R^{9'}$ are each independently ~~selected from~~ H, C_{1-6}-

alk(en/yn)yl, hydroxy-C_{1-6}-alk(en/yn)yl, C_{1-6} alk(en/yn)ylsulfanyl-C_{1-6}-alk(en/yn)yl or C_{3-8}-cycloalk(en)yl; or

R^7 and R^8 together with the atoms to which they are attached ~~nitrogen~~ form a saturated 3-7 membered heterocyclic ring, and R^6 is ~~selected from~~ H, C_{1-6}-alk(en/yn)yl, C_{1-6}-alk(en/yn)yloxy, C_{1-6}-alk(en/yn)ylsulfanyl or C_{3-8}-cycloalk(en)yl, provided that when R^6 is ~~selected from~~ C_{1-6}-alk(en/yn)yloxy or C_{1-6}-alk(en/yn)ylsulfanyl then X is $CR^{11}R^{12}$, wherein R^{11} and R^{12} are each independently ~~are selected from~~ H or C_{1-6} alkyl, and R^9 and $R^{9'}$ are each independently ~~selected from~~ H, C_{1-6}-alk(en/yn)yl, hydroxy-C_{1-6}-alk(en/yn)yl, C_{1-6} alk(en/yn)ylsulfanyl-C_{1-6}-alk(en/yn)yl or C_{3-8}-cycloalk(en)yl; or

R^8 and R^9 together with the atoms to which they are attached and the intervening carbon atom ~~nitrogen~~ form a saturated 3-7 membered heterocyclic ring, and R^6 is ~~selected from~~ H, C_{1-6}-alk(en/yn)yl, C_{1-6}-alk(en/yn)yloxy, C_{1-6}-alk(en/yn)ylsulfanyl or C_{3-8}-cycloalk(en)yl, provided that when R^6 is ~~selected from~~ C_{1-6}-alk(en/yn)yloxy or C_{1-6}-alk(en/yn)ylsulfanyl then X is $CR^{11}R^{12}$, wherein R^{11} and R^{12} are each independently ~~are selected from~~ H or C_{1-6} alkyl, and R^7 is ~~selected from~~ H, C_{1-6}-alk(en/yn)yl or C_{3-8}-cycloalk(en)yl, and $R^{9'}$ is ~~selected from~~ H, C_{1-6}-alk(en/yn)yl, hydroxy-C_{1-6}-alk(en/yn)yl, C_{1-6} alk(en/yn)ylsulfanyl-C_{1-6}-alk(en/yn)yl or C_{3-8}-cycloalk(en)yl;

R^{10} is H, C_{1-6}-alk(en/yn)yl, aryl, aryl-C_{1-6}-alk(en/yn)yl, wherein aryl is optionally substituted with a halogen, CF_3, OCF_3, CN, NO_2 or C_{1-6}-alk(en/yn)yl,[[;]] or an alkali metal;

or a pharmaceutically acceptable salt thereof~~, such as a pharmaceutically acceptable salt~~.

2. (Currently amended) The compound of claim 1 wherein X is ~~selected from~~ O or CH_2.

3. (Currently amended) The compound of claim 1 ~~any one of claims 1-2~~ wherein Y is O.

4. (Currently amended) The compound of claim 1 ~~any one of claims 1-2~~ wherein Y is S.

5. (Currently amended) The compound of claim 1 ~~any one of the preceding claims~~ wherein R^1 is ~~selected from~~ hydrogen, C_{1-6}-alkyl, halogen, phenyl, or phenyl substituted with one or two subtituents selected from C_{1-6}-alkyl and ~~or~~ C_{1-6}-alkoxy.

6. (Currently amended) The compound of claim 1 ~~any one of the preceeding claims~~ wherein R^2 is ~~selected from~~ hydrogen; cyano; C_{1-6}-alkyl; halogen; phenyl; phenyl substituted with one or two subtituents selected from cyano, C_{1-6}-alkyl, C_{1-6}-alkoxy, and ~~or~~ C_{1-6}-alkylsulfonyl; $-NR^{13}R^{14}$ wherein R^{13} and R^{14} together with the nitrogen atom to which they are attached form a 3-7-membered heterocyclic ring which optionally contains one further heteroatom selected from O, S and ~~or~~ N~~, such as morpholinyl, or piperidinyl~~; or monocyclic heteroaryl~~, such as pyrimidinyl~~.

7. (Currently amended). The compound of claim 1 ~~any one of the preceeding claims~~ wherein R^3 is ~~selected from~~ hydrogen; C_{1-6}-alkyl; halogen; phenyl; phenyl substituted with one or two subtituents selected from cyano, C_{1-6}-alkyl, and ~~or~~ C_{1-6}-alkoxy; or monocyclic heteroaryl~~, such as thiophenyl~~.

8. (Currently amended) The compound of claim 1 ~~any one of the preceeding claims~~ wherein R^4 is ~~selected from~~ hydrogen, C_{1-6}-alkyl, halogen, phenyl or phenyl substituted with one or two ~~subtituents~~ substituents selected from C_{1-6}-alkyl and ~~or~~ C_{1-6}-alkoxy.

9. (Currently amended) The compound of claim 1 ~~any one of the preceeding claims~~ wherein R^5 is phenyl, optionally substituted with a halogen, C_{1-6}-alkyl, C_{1-6}-alkyloxy, C_{1-6}-alkylsulfanyl, or halo-C_{1-6}-alkyl.

10. (Currently amended) The compound of claim 1 ~~any one of the preceeding claims~~ wherein R^6 is ~~selected from~~ H or C_{1-6}-alkyl.

11. (Currently amended) The compound of claim 1 ~~any one of the preceeding claims~~ wherein R^7 is ~~selected from~~ H or C_{1-6}-alkyl.

12. (Currently amended) The compound of claim 1 ~~any one of the preceding claims~~ wherein R^8 is ~~selected from~~ H, C_{1-6}-alkyl or C_{3-8}-cycloalkyl.

13. (Currently amended) The compound of claim 1 ~~any one of the preceding claims~~ wherein R^9 and $R^{9'}$ are each independently ~~selected from~~ H or C_{1-6}-alkyl.

14. (Currently amended) The compound of claim 1 ~~any one of the preceding claims~~ wherein R^{10} is H.

15. (Currently amended) The compound of claim 1 ~~any one of claims 1-9 or 14~~ wherein R^6 and R^8 together with the atoms to which they are attached and the intervening carbon atom ~~nitrogen~~ form a 1-pyrrolidinyl, 1-piperidinyl or 1-azepinyl, optionally substituted with a C_{1-6}-alkyl, and R^7 is ~~selected from~~ H, C_{1-6}-alk(en/yn)yl or C_{3-8}-cycloalk(en)yl, and R^9 and $R^{9'}$ are each independently ~~selected from~~ H, C_{1-6}-alk(en/yn)yl, hydroxy-C_{1-6}-alk(en/yn)yl, C_{1-6} alk(en/yn)ylsulfanyl-C_{1-6}-alk(en/yn)yl or C_{3-8}-cycloalk(en)yl.

16. (Currently amended) The compound of claim 1 ~~any one of claims 1-9 or 14~~ wherein R^7 and R^8 together with the atoms to which they are attached ~~nitrogen~~ form a 1-pyrrolidinyl, 1-piperidinyl or 1-azepinyl, optionally substituted with a C_{1-6}-alkyl, and R^6 is ~~selected from~~ H, C_{1-6}-alk(en/yn)yl, C_{1-6}-alk(en/yn)yloxy, C_{1-6}-alk(en/yn)ylsulfanyl or C_{3-8}-cycloalk(en)yl, provided that when R^6 is ~~selected from~~ C_{1-6}-alk(en/yn)yloxy or C_{1-6}-alk(en/yn)ylsulfanyl then X is $CR^{11}R^{12}$, wherein R^{11} and R^{12} are each independently ~~are selected from~~ H or C_{1-6} alkyl, and R^9 and

$R^{9'}$ are independently ~~selected from~~ H, C_{1-6}-alk(en/yn)yl, hydroxy-C_{1-6}-alk(en/yn)yl, C_{1-6} alk(en/yn)ylsulfanyl-C_{1-6}-alk(en/yn)yl or C_{3-8}-cycloalk(en)yl.

17. (Currently amended) The compound of claim 1 ~~any one of claims 1-9 or 14~~ wherein R^8 and R^9 together with the atoms to which they are attached and the intervening carbon atom ~~nitrogen~~ form a 1-pyrrolidinyl, 1-piperidinyl or 1-azepinyl, optionally substituted with a C_{1-6}-alkyl, and R^6 is ~~selected from~~ H, C_{1-6}-alk(en/yn)yl, C_{1-6}-alk(en/yn)yloxy, C_{1-6}-alk(en/yn)ylsulfanyl or C_{3-8}-cycloalk(en)yl, provided that when R^6 is ~~selected from~~ C_{1-6}-alk(en/yn)yloxy or C_{1-6}-alk(en/yn)ylsulfanyl then X is $CR^{11}R^{12}$, wherein R^{11} and R^{12} are each independently ~~are selected from~~ H or C_{1-6} alkyl, and R^7 is ~~selected from~~ H, C_{1-6}-alk(en/yn)yl or C_{3-8}-cycloalk(en)yl, and $R^{9'}$ is ~~selected from~~ H, C_{1-6}-alk(en/yn)yl, hydroxy-C_{1-6}-alk(en/yn)yl, C_{1-6} alk(en/yn)ylsulfanyl-C_{1-6}-alk(en/yn)yl or C_{3-8}-cycloalk(en)yl.

18. (Currently amended) The compound of claim 1 selected from
(S)-1-{2-[2-(4-Fluoro-phenylsulfanyl)-phenoxy]-ethyl}-pyrrolidine-2-carboxylic acid,
(S)-1-{2-[2-(4-tert-Butyl-phenylsulfanyl)-phenoxy]-ethyl}-pyrrolidine-2-carboxylic acid,
(S)-1-{2-[2-(4-Trifluoromethyl-phenylsulfanyl)-phenoxy]-ethyl}-pyrrolidine-2-carboxylic acid,
(S)- 1-{2-[2-(3-Fluoro-phenylsulfanyl)-phenoxy]-ethyl}-pyrrolidine-2-carboxylic acid,
(S)-{2-[2-(4-Chloro-phenylsulfanyl)-phenoxy]-ethyl}-pyrrolidine-2-carboxylic acid,
(S)-1-{2-[2-(3-Chloro-phenylsulfanyl)-phenoxy]-ethyl}-pyrrolidine-2-carboxylic acid,
(S)-1-{2-[2-(3,4-Dichloro-phenylsulfanyl)-phenoxy]-ethyl}-pyrrolidine-2-carboxylic acid,
(S)-1-{2-[2-(3-Chloro-4-fluoro-phenylsulfanyl)-phenoxy]-ethyl}-pyrrolidine-2-carboxylic acid,
(S)-1-{2-[2-(3-Chloro-phenoxy)-phenoxy]-ethyl}-pyrrolidine-2-carboxylic acid,
(S)-1-{2-[2-(4-Chloro-phenoxy)-phenoxy]-ethyl}-pyrrolidine-2-carboxylic acid,
(S)-1-{2-[2-(4-Methoxy-phenoxy)-phenoxy]-ethyl}-pyrrolidine-2-carboxylic acid,
(S)-1-{2-[2-(3,4-Difluoro-phenoxy)-phenoxy]-ethyl}-pyrrolidine-2-carboxylic acid,
1-{2(R/S)-[2-(4-Chloro-phenoxy)-phenoxy]-propyl}-pyrrolidine-2(S)-carboxylic acid,
1-{2(R/S)-[2-(3,4-Difluoro-phenoxy)-phenoxy]-propyl}-pyrrolidine-2(S)-carboxylic acid,
(S)-1-{2-[2-(3-Fluoro-phenoxy)-phenoxy]-ethyl}-pyrrolidine-2-carboxylic acid,

1-{2(R/S)-[2-(3-Fluoro-phenoxy)-phenoxy]-propyl}-pyrrolidine-2(S)-carboxylic acid,

1-{2(R/S)-[2-(3-Fluoro-phenylsulfanyl)-phenoxy]-propyl}-pyrrolidine-2(S)-carboxylic acid,

1-{2(R/S)-[2-(3-Chloro-phenylsulfanyl)-phenoxy]-propyl}-pyrrolidine-2(S)-carboxylic acid,

({2-[2-(4-tert-Butyl-phenylsulfanyl)-phenoxy]-ethyl}-N-ethyl-amino)-acetic acid,

2-{3-[2-(4-tert-Butyl-phenylsulfanyl)-phenoxy]-pyrrolidin-1-yl}-propionic acid,

({2-[2-(3-Chloro-phenylsulfanyl)-phenoxy]-ethyl}-N--methyl-amino)-acetic acid,

({2-[2-(3-Chloro-4-fluoro-phenylsulfanyl)-phenoxy]-ethyl}-N-methyl-amino)-acetic acid,

{2-[2-(4-tert-Butyl-phenylsulfanyl)-phenoxymethyl]-piperidin-1-yl}-acetic acid,

({2-[2-(3-Fluoro-phenylsulfanyl)-phenoxy]-ethyl}-N-methyl-amino)-acetic acid,

{4-[2-(4-tert-Butyl-phenylsulfanyl)-phenoxy]-piperidin-1-yl}-acetic acid,

(N-2-propyl-{2-[2-(4-trifluoromethyl-phenylsulfanyl)-phenoxy]-ethyl}-amino)-acetic acid,

({2-[2-(3,4-Dichloro-phenylsulfanyl)-phenoxy]-ethyl}-N-ethyl-amino)-acetic acid,

(N-Ethyl-{2-[2-(4-methylsulfanyl-phenylsulfanyl)-phenoxy]-ethyl}-amino)-acetic acid,

2-{3-[2-(3,4-Dichloro-phenylsulfanyl)-phenoxy]-pyrrolidin-1-yl}-propionic acid,

(S)-{3-[2-(4-tert-Butyl-phenylsulfanyl)-phenoxy]-pyrrolidin-1-yl}-acetic acid,

({2-[2-(3-Chloro-4-fluoro-phenylsulfanyl)-phenoxy]-ethyl}-N-ethyl-amino)-acetic acid,

(N-2-propyl-{2-[2-(4-methylsulfanyl-phenylsulfanyl)-phenoxy]-ethyl}-amino)-acetic acid,

{3-[2-(4-tert-Butyl-phenylsulfanyl)-phenoxy]-pyrrolidin-1-yl}-acetic acid,

({2-[2-(3-Chloro-phenylsulfanyl)-phenoxy]-ethyl}-N-ethyl-amino)-acetic acid,

({2-[2-(4-Chloro-phenylsulfanyl)-phenoxy]-ethyl-}N-methyl-amino)-acetic acid,

{4-[2-(3,4-Dichloro-phenylsulfanyl)-phenoxy]-piperidin-1-yl}-acetic acid,

2-{3-[2-(4-Trifluoromethyl-phenylsulfanyl)-phenoxy]-pyrrolidin-1-yl}-propionic acid,

({2-[2-(4-tert-Butyl-phenylsulfanyl)-phenoxy]-ethyl}-N-2-propyl-amino)-acetic acid

({2-[2-(4-tert-Butyl-phenylsulfanyl)-phenoxy]-ethyl}-N-methyl-amino)-acetic acid,

{2-[2-(4-Methylsulfanyl-phenylsulfanyl)-phenoxymethyl]-piperidin-1-yl}-acetic acid,

({2-[2-(3,4-Dichloro-phenylsulfanyl)-phenoxy]-ethyl}-N-methyl-amino)-acetic acid,

(N-Methyl-{2-[2-(4-trifluoromethyl-phenylsulfanyl)-phenoxy]-ethyl}-amino)-acetic acid,

2-{3(R)-[2-(4-tert-Butyl-phenylsulfanyl)-phenoxy]-pyrrolidin-1-yl}-propionic acid,

2-{3(R)-[2-(3,4-Dichloro-phenylsulfanyl)-phenoxy]-pyrrolidin-1-yl}-propionic acid,

2-[3(R)-(2-(4-methylphenyl)-sulfanyl-phenoxy)-pyrrolidin-1-yl]-propionic acid,

{3(R)-[2-(4-tert-Butyl-phenylsulfanyl)-phenoxy]-pyrrolidin-1-yl}-acetic acid,

2-{3(R)-[2-(4-Trifluoromethyl-phenylsulfanyl)-phenoxy]-pyrrolidin-1-yl}-propionic acid,

2-{3(R)-[2-(4-Chloro-phenylsulfanyl)-phenoxy]-pyrrolidin-1-yl}-propionic acid,

({1-[2-(3-Chloro-phenylsulfanyl)-phenoxymethyl]-propyl}-N-ethyl-amino)-acetic acid,

({1-[2-(3,4-Dichloro-phenylsulfanyl)-phenoxy)-butan-2-yl}-N-ethyl-amino)-acetic acid,

({1-[2-(3,4-Dichloro-phenylsulfanyl)-phenoxy]-butan-3-methyl-2-yl}-N-ethyl-amino)-acetic acid,

({1-[2-(3-Chloro-4-fluoro-phenylsulfanyl)-phenoxy]-butan-2-yl}-N-ethyl-amino)-acetic acid,

({1-[1-(3-Chloro-phenylsulfanyl)-phenoxy]-propan-2-yl}-N-ethyl-amino)-acetic acid,

({1-[2-(3-Chloro-4-fluoro-phenylsulfanyl)-phenoxy]-butan-4-methyl-2-yl)}-N-ethyl-amino)-acetic acid,

({1-[2-(3-Chloro-4-fluoro-phenylsulfanyl)-phenoxy]propan-2-yl}-N-ethyl-amino)-acetic acid,

(S)-{1-[2-(3-Chloro-phenylsulfanyl)-phenoxy]-propan-2-yl }-N-methyl-amino)-acetic acid ,

(S)-({1-[2-(3-Chloro-phenylsulfanyl)-phenoxy]-propan-2-yl)-N-ethyl-amino)-acetic acid,

({1-[2-(3,4-Dichloro-phenylsulfanyl)-phenoxy]-propan-2-yl}-N-ethyl-amino)-acetic acid,

({1-[2-(4-Chloro-phenylsulfanyl)-phenoxy]-propan-2-yl}-N-ethyl-amino)-acetic acid,

({1-[2-(3-Chloro-phenylsulfanyl)-phenoxymethyl]-propyl}-N-methyl-amino)-acetic acid,

({1-[2-(4-Chloro-phenylsulfanyl)-phenoxymethyl]-propyl}-N-ethyl-amino)-acetic acid,

(N-Ethyl-{1-[2-(3-fluoro-phenylsulfanyl)-phenoxymethyl]-propyl}-amino)-acetic acid,

(R)-({2-[2-(3,4-Dichloro-phenylsulfanyl)-phenoxy]-1-methyl-ethyl}-N-ethyl-amino)-acetic acid,

(S)-(2{2-[2-(4-Chloro-phenoxy)-phenoxy]-propyl-N-methyl-amino)-acetic acid,

(R)-(2{2-[2-(3-Chloro-phenylsulfanyl)-phenoxy]-}-propyl-N-methyl-amino)-acetic acid,

({2-[2-(3-Fluoro-phenylsulfanyl)-phenoxy]-propyl}-N-methyl-amino)-acetic acid,

({2-[2-(3-Chloro-phenylsulfanyl)-phenoxy]-propan-1yl}-N-ethyl-amino)-acetic acid,

({1-[2-(3-Chloro-phenylsulfanyl)-phenoxy]-3-methyl-butan-2-yl}-N-methyl-amino)-acetic acid,

({3-methyl-1-[2-(4-trifluoromethyl-phenylsulfanyl)-phenoxy]-butan-2-yl}-N-ethyl-amino)-acetic acid,

({1-[2-(3-Chloro-4-fluoro-phenylsulfanyl)-phenoxy]-butan-2-yl}-N-methyl-amino)-acetic acid,

(S)-(1{2-[2-(3-Chloro-4-fluoro-phenylsulfanyl)-phenoxy]-propan-2-yl}N-methyl-amino)-acetic acid,

(S)-(2-{2-[2-(3-Fluoro-phenylsulfanyl)-phenoxy]-propyl}-N-methyl-amino)-acetic acid,

({1-[2-(4-tert-Butyl-phenylsulfanyl)-phenoxy]-3-methyl-butan-2-yl}-N-ethyl-amino)-acetic acid,

(S)-({1-[2-(3,4-Dichloro-phenylsulfanyl)-phenoxy]-propan-2-yl}-N-methyl-amino)-acetic acid,

({1-[2-(3-Chloro-4-fluoro-phenylsulfanyl)-phenoxy]-3-methyl-butan-2-yl)-N-methyl-amino)-acetic acid,

({1-[2-(4-tert-Butyl-phenylsulfanyl)-phenoxy]-3-methyl-propan-2-yl}-N-ethyl-amino)-acetic acid,

({2-[2-(3-Chloro-4-fluoro-phenylsulfanyl)-phenoxy]-propan-1-yl}-N-ethyl-amino)-acetic acid,

({2-[2-(4-methoxy-phenylsulfanyl)-phenoxy]-propan-1-yl}- N-Cyclohexyl -amino)-acetic acid,

{ [2-(2-(4-methylsulfanyl-phenoxy)-propan-1-yl-]-N-cyclohexyl-amino}-acetic acid,

({2-[2-(3-Chloro-phenylsulfanyl)-phenoxy]-propan-1-yl}-N-cyclohexyl-amino)-acetic acid,

(S)-1-{3-[2-(3-Fluoro-phenylsulfanyl)-phenyl]-propyl}-pyrrolidine-2-carboxylic acid,

(S)-2-({2-[3-(3-Fluoro-phenylsulfanyl)-biphenyl-4-yloxy]-ethyl}-methyl-amino)-propionic acid,

({2-[3-(3-Fluoro-phenylsulfanyl)-biphenyl-4-yloxy]-ethyl}-methyl-amino)-acetic acid,

(S)-1-{2-[4-Chloro-2-(3-fluoro-phenylsulfanyl)-phenoxy]-ethyl}-pyrrolidine-2-carboxylic acid,

(S)-1-{2-[3-Chloro-2-(3-fluoro-phenylsulfunyl)-phenoxy]-ethyl}pyrrolidine-2-carboxylic acid,

(S)-1-{2-[5-Chloro-2-(3-fluoro-phenylsulfanyl)-phenoxy]-ethyl}pyrrolidine-2-carboxylic acid,

(S)-1-{2-[4-Cyano-2-(3-fluoro-phenylsulfanyl)-phenoxy]-ethyl}-pyrrolidine-2-carboxylic acid

(S)-1-[2-(5-Chloro-2-phenylsulfanyl-phenoxy)-ethyl]pyrrolidine-2-carboxylic acid,

(S)-1-{2-[3-(3-Fluoro-phenylsulfanyl)-biphenyl-4-yloxy]-ethyl}-pyrrolidine-2-carboxylic acid,

(S)-{2-[4'-Methoxy-3-(3-fluoro-phenylsulfanyl)-biphenyl-4-yloxy]-ethyl}-pyrrolidine-2-carboxylic acid,

(S)-{2-[4'-Cyano-3-(3-fluoro-phenylsulfanyl)-biphenyl-4-yloxy]-ethyl}-pyrrolidine-2-carboxylic acid,

(S)-1-{2-[4'-Cyano-4-(3-fluoro-phenylsulfanyl)-biphenyl-3-yloxy]-ethyl}-pyrrolidine-2-carboxylic acid,

(S)-1-{2-[2-(3-Fluoro-phenylsulfanyl)-5-thiophen-3-yl-phenoxy]-ethyl}-pyrrolidine-2-carboxylic acid,

(S)-1-{2-[2-(3-Fluoro-phenylsulfanyl)-4-pyrimidin-5-yl-phenoxy]-ethyl}-pyrrolidine-2-carboxylic acid,
(S)-1-{2-[3-(3-Fluoro-phenylsulfanyl)-3-methanesulfonyl-biphenyl-4-yloxy]-ethyl}-pyrrolidine-2(S)-carboxylic acid,
(S)-1-{2-[2-(3-Fluoro-phenylsulfanyl)-4-morpholin-4-yl-phenoxy]-ethyl}-pyrrolidine-2-carboxylic acid, and
(S)-1-{2-[2-(3-Fluoro-phenylsulfanyl)-4-piperidin-1-yl-phenoxy]-ethyl}-pyrrolidine-2-carboxylic acid,
or a pharmaceutically acceptable salt thereof.

19. (Currently amended) A pharmaceutical composition comprising a compound according to claim 1 ~~any one of claims 1-18~~ and a pharmaceutically acceptable carrier or diluent.

20. (Canceled)

21. (Currently amended) A method for the treatment of a disease or disorder selected from the group consisting of post-traumatic stress disorder, ~~the positive and the negative symptoms of schizophrenia, including both the positive and the negative symptoms of schizophrenia and other~~ psychoses, ~~and in the improvement of cognition in~~ conditions where the cognitive processes are diminished~~, i.e. Alzheimer's disease, multi-infarct dementia, AIDS dementia, Huntington's disease, Parkinson's disease, amyotrophic lateral sclerosis, or diseases wherein the brain is damaged by inner or outer influence, such as trauma to the head or stroke,~~ and convulsive disorders~~, such as epilepsy, spasticity or myoclonus in a living animal body, including a human~~, comprising administering to a subject in need thereof a therapeutically effective amount of a compound according to claim 1 ~~any one of claims 1-18~~.

22. (New) The method of claim 21, wherein said method is for the treatment of the positive or negative symptoms of schizophrenia.

23. (New) The method of claim 22, wherein said method is for the treatment of both the positive and negative symptoms of schizophrenia.

24. (New) The method of claim 21, wherein said method is for the treatment of Alzheimer's disease, multi-infarct dementia, AIDS dementia, Huntington's disease, Parkinson's disease, amyotrophic lateral sclerosis, or diseases wherein the brain is damaged by inner or outer influence.

25. (New) The method of claim 24, wherein said method is for the treatment of brain damage due to trauma to the head or stroke.

26. (New) The method of claim 21, wherein said method is for the treatment of epilepsy, spasticity or myoclonus.

27. (New) The method of claim 21 wherein said subject is a human.

28. (New) A pharmaceutical composition comprising a compound according to claim 18 and a pharmaceutically acceptable carrier or diluent.